BIOC Stock Overview
GlaxoSmithKline S.A.E. operates as a research-based pharmaceutical and healthcare company.
GlaxoSmithKline S.A.E Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م38.44|
|52 Week High||ج.م38.44|
|52 Week Low||ج.م18.70|
|1 Month Change||71.38%|
|3 Month Change||60.17%|
|1 Year Change||52.60%|
|3 Year Change||94.53%|
|5 Year Change||n/a|
|Change since IPO||312.45%|
Recent News & Updates
|BIOC||EG Pharmaceuticals||EG Market|
Return vs Industry: BIOC exceeded the EG Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: BIOC exceeded the EG Market which returned 15.2% over the past year.
|BIOC Average Weekly Movement||9.7%|
|Pharmaceuticals Industry Average Movement||4.7%|
|Market Average Movement||5.6%|
|10% most volatile stocks in EG Market||9.1%|
|10% least volatile stocks in EG Market||3.4%|
Stable Share Price: BIOC is more volatile than 90% of EG stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BIOC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
|1981||n/a||Amr Mamdouh Majid||https://www.gsk.com/en-gb/contact-us/worldwide/egypt|
GlaxoSmithKline S.A.E. operates as a research-based pharmaceutical and healthcare company. The company was founded in 1981 and is based in Cairo, Egypt. GlaxoSmithKline S.A.E. is a subsidiary of Glaxo Group Limited.
GlaxoSmithKline S.A.E Fundamentals Summary
|BIOC fundamental statistics|
Is BIOC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIOC income statement (TTM)|
|Cost of Revenue||ج.م1.29b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.50|
|Net Profit Margin||10.21%|
How did BIOC perform over the long term?See historical performance and comparison